Description of Procedure or Service

Magnetoencephalography (MEG) is a noninvasive functional imaging technique in which the weak magnetic forces associated with the electrical activity of the brain are recorded externally on the scalp. Using mathematical modeling, the recorded data are then analyzed to provide an estimated location of the electrical activity. This information can be superimposed on an anatomic image of the brain, typically a magnetic resonance imaging (MRI) scan, to produce a functional/anatomic image of the brain, referred to as magnetic source imaging (MSI). The primary advantage of MSI is that while the conductivity and thus measurement of electrical activity as recorded by the electroencephalogram (EEG) is altered by surrounding brain structures, the magnetic fields are not. Therefore, MSI permits a high resolution image.

Detection of weak magnetic fields requires gradiometer detection coils coupled to a superconducting quantum interference device, which requires a specialized room shielded from other magnetic sources. Mathematical modeling programs based on idealized assumptions are then used to translate detected signals into functional images. In its early evolution, clinical applications were limited by the use of only 1 detection coil requiring lengthy imaging times, which, because of body movement, also were difficult to match with the MRI. However, more recently, the technique has evolved to multiple detection coils in an array that can provide data more efficiently over a wide extracranial region.

One clinical application is localization of the pre- and postcentral gyri as a guide to surgical planning in patients scheduled to undergo neurosurgery for epilepsy, brain neoplasms, arteriovenous malformations, or other brain disorders. These gyri contain the "eloquent" sensorimotor areas of the brain, the preservation of which is considered critical during any type of brain surgery. Localization of the eloquent cortex often requires such intraoperative invasive functional techniques as cortical stimulation with the patient under local anesthesia or somatosensory-evoked responses on electrocorticography. While these techniques can be done at the same time as the planned resection, they are cumbersome and can add up to 45 minutes of anesthesia time. Furthermore, sometimes these techniques can be limited by the small surgical field. A preoperative test which is often used to localize the eloquent hemisphere is the Wada test. MEG/MSI has been proposed as a substitute for the Wada test.

Another related clinical application is localization of epileptic foci, particularly for screening of surgical candidates and surgical planning. In a small subset of patients, extended electrocorticography or stereotactic electroencephalography with implanted electrodes is considered the gold standard for localizing epileptogenic foci. MEG/MSI has principally been investigated as a supplement to or an alternative to invasive monitoring.

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.
Magnetoencephalography/Magnetic Source Imaging

Policy

BCBSNC will provide coverage for Magnetoencephalography/Magnetic Source Imaging when it is determined to be medically necessary because the medical criteria and guidelines shown below have been met.

Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When Magnetoencephalography/Magnetic Source Imaging is covered

Magnetoencephalography/magnetic source imaging may be considered medically necessary as a substitute for the Wada test, for the purpose of determining the laterality of language function, in patients being prepared for surgery for epilepsy, brain tumors, and other indications requiring brain resection.

Magnetoencephalography/magnetic source imaging as part of the preoperative evaluation of patients with drug-resistant epilepsy (seizures refractory to at least 2 first line anticonvulsants) may be considered medically necessary when standard techniques, such as MRI and EEG, do not provide satisfactory localization of the epileptic lesion(s).

When Magnetoencephalography/Magnetic Source Imaging is not covered

Magnetoencephalography and magnetic source imaging are considered investigational for all other indications. BCBSA does not provide coverage for investigational services or procedures.

Policy Guidelines

For individuals who have drug-resistant epilepsy and are being evaluated for possible resective surgery who receive MEG/MSI, the evidence for MEG/MSI as an adjunct to standard clinical workup includes various types of case series. Relevant outcomes are test accuracy and functional outcomes. Published evidence on MEG is suboptimal, with no clinical trials demonstrating clinical utility. Literature on diagnostic accuracy has methodologic limitations, primarily selection and ascertainment bias. Studies of functional outcomes do not fully account for the effects of MEG, because subjects who received MEG were not fully accounted for in the studies. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have brain lesions and a planned brain resection who receive MEG/MSI, the evidence for MEG/MSI for localization of eloquent function areas includes comparative studies. Relevant outcomes include test accuracy and functional outcomes. Available studies have reported that this test has high concordance with the Wada test, which is currently the main alternative to localize eloquent functions. Management is changed in some patients based on MEG testing, but it has not been demonstrated that these changes lead to improved outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

Billing/Coding/Physician Documentation Information
Magnetoencephalography/Magnetic Source Imaging

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

**Applicable service codes:** 95965, 95966, 95967, S8035

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Medical Term Definitions

**Wada Test**

unilateral internal carotid injection of amobarbital to determine the laterality of speech; injection on the dominant side causes transient aphasia or mutism; used prior to surgical treatment of epilepsy

Scientific Background and Reference Sources


Magnetoencephalography/Magnetic Source Imaging


Policy Implementation/Update Information

3/02 Original policy issued.
1/03 Code S8035 added to Billing/Coding section. System coding changes.
5/04 Benefits Application and Billing/Coding sections updated for consistency.
6/16/08 References updated. Specialty Matched Consultant Advisory Panel review 5/15/08. No change in policy statement. (adn)
3/30/09 Description of procedure expanded for clarity. Policy statement changed: magnetoencephalography/Magnetic Source Imaging is covered when the medical necessity criteria are met. Statement in the When MEG/MSI is Covered section changed to read, "Magnetoencephalography may be considered medically necessary for the purpose of determining the laterality of language function, as a substitute for the Wada test, in patients undergoing diagnostic workup for evaluation of surgery for epilepsy, brain tumors, and other indications requiring brain resection." Statement in the When MEG/MSI is Not Covered revised to read, "MEG and MSI are considered investigational for all other indications, including localization of seizure focus for patients undergoing evaluation for surgical treatment of intractable seizures." References updated. (adn)
6/22/10 Policy Number(s) removed (amw)
9/28/10 Statement in the When MEG/MSI is Covered section reworded for clarity: Magnetoencephalography may be considered medically necessary for the purpose of determining the laterality of language function, as a substitute for the Wada test, in patients undergoing diagnostic workup for evaluation of surgery for epilepsy and for localization of eloquent and sensorimotor areas prior to surgery for epilepsy, brain tumors, and other indications requiring brain resection. Specialty Matched Consultant Advisory Panel review 8/25/10. Draft accepted as written. (adn)
7/19/11 Specialty Matched Consultant Advisory Panel review 6/29/11. Policy accepted as written. (adn)
8/30/11 Description section revised. The statement in the When MEG/MSI Is Covered section was revised to read: Magnetoencephalography/magnetic source imaging may be considered medically necessary as a substitute for the Wada test for the purpose of determining the laterality of language function in patients being prepared for surgery for epilepsy, brain tumors, and other indications requiring brain resection. Magnetoencephalography/magnetic
Magnetoencephalography/Magnetic Source Imaging

source imaging as part of the preoperative evaluation of patients with intractable epilepsy (seizures refractory to medical therapy) may be considered medically necessary when standard techniques, such as MRI and EEG do not provide satisfactory localization of the epileptic lesion(s). The statement in the When MEG/MSI Is Not Covered section was revised to read: Magnetoencephalography and magnetic source imaging are considered investigational for all other indications. BCBSA does not provide coverage for investigational services or procedures. Coverage rationale in the Policy Guidelines section updated. (adn)

7/10/12 Specialty Matched Consultant Advisory Panel review 6/20/12. (sk)
11/13/12 Reference added. No change to Policy guideline. (sk)
7/30/13 Specialty Matched Consultant Advisory Panel review 7/17/13. No change to Policy statement. (sk)
11/26/13 Reference added. No change to Policy statement. (sk)
8/12/14 Specialty Matched Consultant Advisory Panel review 7/29/14. No change to Policy statement. (sk)
11/11/14 Reference added. No change to policy statement. (lpr)
7/28/15 Specialty Matched Consultant Advisory Panel review 6/24/2015. No change to policy statement. (lpr)
2/29/16 Updated Description and Policy Guidelines sections. Reference added. No change to policy statement. (lpr)
7/26/16 Specialty Matched Consultant Advisory Panel review 6/29/2016. No change to policy statement. (an)
6/30/17 Specialty Matched Consultant Advisory Panel review 5/26/2017. No change to policy statement. (an)
11/10/17 In the coverage statement, the word “intractable” deleted and replace with “drug-resistant” epilepsy. Policy Guidelines updated. Reference added. (an)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.